Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977324 | 0.88 | CRBN (0.42) | OPRK1CRBNDRD2DRD3CYP19A1 | |
| SCHEMBL3972863 | 0.80 | CYP11B2 (0.48) | CA1CA2ACHEDRD2DRD3 | |
| SCHEMBL3974195 | 0.76 | ACHE (0.41) | CRBNNOTUMCA1CA2ACHE | |
| SCHEMBL3974203 | 0.75 | ACHE (0.40) | OPRK1NOTUMCA1CA2ACHE | |
| SCHEMBL3974200 | 0.75 | ACHE (0.40) | OPRK1NOTUMCA1CA2ACHE | |
| SCHEMBL1099201 | 0.75 | HTR2C (0.46) | CRBNNOTUMACHEL3MBTL1ALDH1A1 | |
| SCHEMBL6406234 | 0.75 | DRD2 (0.51) | CA1CA2ACHEDRD2DRD3 | |
| SCHEMBL6406230 | 0.75 | DRD2 (0.51) | CA1CA2ACHEDRD2DRD3 | |
| SCHEMBL6387682 | 0.74 | OPRK1 (0.50) | OPRK1CA1CA2ACHEDRD2 | |
| SCHEMBL18983710 | 0.74 | OPRK1 (0.50) | OPRK1CA1CA2ACHEDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554240-B1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-06 | — | — | EP | disclosed |
| US-7351857-B2 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| US-20060247314-A1 | Substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-04 | — | — | US | disclosed |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-06 | — | — | US | disclosed |
| EP-1569897-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1556344-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1554240-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-20 | — | — | EP | disclosed |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-02 | — | — | US | disclosed |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | US | disclosed |
| WO-2004037779-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037777-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037778-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | OPRK1 1822/4885CRBN 1802/4885NOTUM 3401/4885 |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | OPRK1 1671/4885CRBN 1552/4885NOTUM 1842/4885 |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | OPRK1 1822/4885CRBN 1802/4885NOTUM 3401/4885 |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | OPRK1 1822/4885CRBN 1802/4885NOTUM 3401/4885 |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | OPRK1 1671/4885CRBN 1552/4885NOTUM 1842/4885 |
| US-20060247314-A1 | Substituted tetralins and indanes | PPARA, PPARG, PPARD | OPRK1 2634/4885CRBN 1047/4885NOTUM 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.